NAX Strengthens Leadership Team With Appointment of Patrick Nicolet - Former Capgemini Group CTO
9.9.2021 15:00:00 EEST | Business Wire | Press release
New Asset eXchange (NAX), a company that creates new markets and ecosystems around corporate assets, has today announced the appointment of Patrick Nicolet as Chair of its technology platform, Bridge.
Patrick Nicolet - formerly Group CTO and Executive Board Member at Capgemini - will lead NAX’s technology platform as it works on the development and deployment of enterprise-grade solutions to power digital asset economies. The platform’s current focus areas include coin & tokenization solutions, payment & disbursement processing, aggregated blockchain solutions and deployment services.
The arrival of Patrick Nicolet coincides with the appointment of Dr. Heiner Leisten as Chair of the Genesis Project, NAX’s development platform, and Joe Euteneuer as Chair of LiQid, NAX’s securitization platform. Both already sit on the NAX Board alongside high-profile business figures such as Frank Strauß, former Global CEO of Private and Commercial Banking at Deutsche Bank.
Jeff Schumacher, CEO and Founder, NAX said: “Patrick is a world-class technologist and business leader and brings vast experience to the team. His arrival further strengthens the NAX ecosystem; a development platform that mines corporate assets to create asset-backed ventures and markets, a technology platform that provides technology tools and solutions to power digital assets, and a securitization platform to make corporate assets tradeable. With Heiner, Patrick, and Joe at the helm of each, alongside our broader leadership team, we’re building an infrastructure that can fully realize the trillions of dollars of dormant value residing in corporate assets.”
NAX formally launched in January 2021 after two and a half years in stealth development. It focuses on building new markets and ecosystems around corporate assets. Led by serial entrepreneur Jeff Schumacher, NAX comprises three distinct but complementary platforms that provide a new lifecycle to repurpose corporate assets:
-
Creating asset backed ventures and markets
NAX’s development platform Genesis Project mines dormant corporate assets to create asset-backed ventures and markets.
-
Leveraging assets for DeFi
NAX’s technology platform Bridge deploys enterprise-grade technology solutions to power digital asset economies.
-
Making alternative assets tradeable
NAX’s trading platform LiQid securitizes corporate assets to make them tradeable.
Schumacher added: “The vast majority of assets globally are not listed. At NAX, we’re building an infrastructure to change that. From seed to securitization, we unlock value from underutilized corporate assets and, in doing so, are building next generation markets.”
About NAX
NAX enables a corporate partner to realize the full potential of its proprietary assets through the development of new asset-backed ventures and securities.
From seed to securitization, NAX co-leads the commercialization of these initiatives alongside its partners. It has three distinct but complementary platforms to repurpose corporate assets: a development platform, a technology platform and a securitization platform.
NAX maintains its headquarters in Manhattan Beach, CA and has offices in Palo Alto, New York, London, Paris, Zurich and Frankfurt.
For more information, visit http://www.naxgrp.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210909005501/en/
Contact information
Media contacts
Vested
Danny Calogero
nax@fullyvested.com
+447891 563 294
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Leaders of Dubai-Based Unicorns Hail City as Global Innovation Hub Shaping Future Technology and Driving the Digital Economy20.4.2026 16:08:00 EEST | Press release
Leaders of Dubai-based unicorn companies have reaffirmed the emirate’s status as a global hub for digital innovation and technology-led growth. The senior executives highlighted Dubai’s forward-looking regulatory environment, advanced infrastructure, and ability to attract international talent as key factors strengthening its appeal for high-growth digital businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420503062/en/ Leaders of Dubai-based unicorns hail city as global innovation hub shaping future technology and driving the digital economy (Photo: AETOSWire) They noted that Dubai has evolved into a strategic launchpad for ambitious companies, offering an agile business environment that supports innovation and enables expansion into regional and international markets. The business leaders also praised the strong alignment between the public and private sectors within Dubai’s digital ecosystem, supported by Dubai
Capcom’s All-New IP PRAGMATA Surpasses One Million Units Sold in Two Days!20.4.2026 16:00:00 EEST | Press release
Capcom Co., Ltd. (TOKYO:9697) today announced that worldwide sales of PRAGMATA, the company’s all-new IP released on April 17, 2026*, have surpassed one million units. PRAGMATA is a science-fiction action-adventure game that depicts the journey of Hugh Williams and Diana, an android girl, in a near-future lunar world. A completely new IP, PRAGMATA was developed primarily by a team of younger Capcom developers, who created an innovative gameplay experience by fusing action gameplay with puzzle elements set within a distinctive world ruled over by artificial intelligence. In the absence of an established fan base or preexisting brand recognition, Capcom implemented a range of marketing initiatives—beginning with the early release of a playable demo—to communicate the unique features of the game to a wider audience. In addition, in line with the company’s multi-platform strategy, Capcom broadened the title’s availability by adding support for Nintendo Switch™ 2 at an early stage. As a res
Capcom’s All-New IP PRAGMATA Surpasses One Million Units Sold in Two Days!20.4.2026 16:00:00 EEST | Press release
Capcom Co., Ltd. (TOKYO:9697) today announced that worldwide sales of PRAGMATA, the company’s all-new IP released on April 17, 2026*, have surpassed one million units. PRAGMATA is a science-fiction action-adventure game that depicts the journey of Hugh Williams and Diana, an android girl, in a near-future lunar world. A completely new IP, PRAGMATA was developed primarily by a team of younger Capcom developers, who created an innovative gameplay experience by fusing action gameplay with puzzle elements set within a distinctive world ruled over by artificial intelligence. In the absence of an established fan base or preexisting brand recognition, Capcom implemented a range of marketing initiatives—beginning with the early release of a playable demo—to communicate the unique features of the game to a wider audience. In addition, in line with the company’s multi-platform strategy, Capcom broadened the title’s availability by adding support for Nintendo Switch™ 2 at an early stage. As a res
Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer20.4.2026 15:30:00 EEST | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of its PKMYT1 inhibitor, lunresertib (Debio2513), and its WEE1 inhibitor, zedoresertib (Debio 0123). The designation is for the treatment of adult patients with CCNE1 amplified, or a deleterious mutation in either FBXW7 or PPP2R1A, platinum-resistant/refractory ovarian cancer. The FDA’s Fast Track program is designed to facilitate the development and expedite the review of new drugs intended to treat serious conditions and fill an unmet medical need. Programs granted Fast Track designation benefit from more frequent communication with the FDA and, if relevant criteria are met, may be eligible for Priority Review and Accelerated Approval of a New Drug Application (NDA). Momentum Following AACR O
Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer20.4.2026 15:30:00 EEST | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of its PKMYT1 inhibitor, lunresertib (Debio2513), and its WEE1 inhibitor, zedoresertib (Debio 0123). The designation is for the treatment of adult patients with CCNE1 amplified, or a deleterious mutation in either FBXW7 or PPP2R1A, platinum-resistant/refractory ovarian cancer. The FDA’s Fast Track program is designed to facilitate the development and expedite the review of new drugs intended to treat serious conditions and fill an unmet medical need. Programs granted Fast Track designation benefit from more frequent communication with the FDA and, if relevant criteria are met, may be eligible for Priority Review and Accelerated Approval of a New Drug Application (NDA). Momentum Following AACR O
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom